NASDAQ:ABEO - Abeona Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $7.05 -0.37 (-4.99 %) (As of 05/22/2019 12:56 PM ET)Previous Close$7.42Today's Range$6.99 - $7.4052-Week Range$6.26 - $18.90Volume1,201 shsAverage Volume390,751 shsMarket Capitalization$346.59 millionP/E RatioN/ADividend YieldN/ABeta1.92 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas. Receive ABEO News and Ratings via Email Sign-up to receive the latest news and ratings for ABEO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ABEO Previous SymbolOTCMKTS:ACCP CUSIPN/A CIK318306 Webhttp://www.abeonatherapeutics.com/ Phone214-665-9495Debt Debt-to-Equity Ratio0.06 Current Ratio3.35 Quick Ratio4.37Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3 million Price / Sales115.53 Cash FlowN/A Price / Cash FlowN/A Book Value$2.40 per share Price / Book2.94Profitability EPS (Most Recent Fiscal Year)($1.19) Net Income$-56,670,000.00 Net Margins-960.91% Return on Equity-45.58% Return on Assets-38.43%Miscellaneous EmployeesN/A Outstanding Shares49,162,000Market Cap$346.59 million Next Earnings Date8/8/2019 (Estimated) OptionableOptionable Abeona Therapeutics (NASDAQ:ABEO) Frequently Asked Questions What is Abeona Therapeutics' stock symbol? Abeona Therapeutics trades on the NASDAQ under the ticker symbol "ABEO." How were Abeona Therapeutics' earnings last quarter? Abeona Therapeutics Inc (NASDAQ:ABEO) released its quarterly earnings data on Monday, March, 18th. The biopharmaceutical company reported ($0.36) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.42) by $0.06. The biopharmaceutical company had revenue of $0.50 million for the quarter, compared to the consensus estimate of $1.66 million. Abeona Therapeutics had a negative net margin of 960.91% and a negative return on equity of 45.58%. View Abeona Therapeutics' Earnings History. When is Abeona Therapeutics' next earnings date? Abeona Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, August 8th 2019. View Earnings Estimates for Abeona Therapeutics. What price target have analysts set for ABEO? 7 brokers have issued 1 year price objectives for Abeona Therapeutics' shares. Their forecasts range from $17.00 to $30.00. On average, they anticipate Abeona Therapeutics' share price to reach $26.4286 in the next year. This suggests a possible upside of 274.9% from the stock's current price. View Analyst Price Targets for Abeona Therapeutics. What is the consensus analysts' recommendation for Abeona Therapeutics? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abeona Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Abeona Therapeutics. What are Wall Street analysts saying about Abeona Therapeutics stock? Here are some recent quotes from research analysts about Abeona Therapeutics stock: 1. Cantor Fitzgerald analysts commented, ": We are reiterating our OW rating and $29 12-month price target on Abeona following 1Q19 earnings. Abeona announced the CMC work for the Phase 3 VITAL study in EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) has been completed. The trial could initiate in mid-2019, following the completion of the last checkbox regarding an ongoing FDA review. While specific timeline guidance has not been provided, pre-screening has begun, which could support a more rapid enrollment. Additionally, the company expects to announce interim data from the Sanfilippo Phase 1/2 studies." (5/14/2019) 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We ascribe a total risk-adjusted net present value (rNPV) of $1.46B to Abeona’s technology platforms, which yields a price per share of $30.00 based on about 48M shares outstanding as of end-2019. We utilize an 85% probability of success for EB-101." (5/6/2019) 3. Maxim Group analysts commented, "Abeona reported positive preclinical data for their AIM vector platform using the AAV204 capsid in cystic fibrosis (CF) and retinal diseases at the American Society of Gene and Cell Therapy and, Association for Research in Vision and Ophthalmology, respectively." (5/1/2019) 4. According to Zacks Investment Research, "Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States. " (3/20/2019) 5. Mizuho analysts commented, "We believe phase 1/2 data, including patient-reported outcomes, was encouraging and with a 3-month primary endpoint, we expect top-line data could be available in 1H20. We also note that the pivotal trial will include children (the phase 1/2 trial enrolled adults only)." (12/10/2018) Has Abeona Therapeutics been receiving favorable news coverage? Media coverage about ABEO stock has trended neutral this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Abeona Therapeutics earned a daily sentiment score of 0.2 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. Who are some of Abeona Therapeutics' key competitors? Some companies that are related to Abeona Therapeutics include Esperion Therapeutics (ESPR), Gossamer Bio (GOSS), Opko Health (OPK), Aimmune Therapeutics (AIMT), Mallinckrodt (MNK), Corcept Therapeutics (CORT), Phibro Animal Health (PAHC), Apellis Pharmaceuticals (APLS), Theravance Biopharma (TBPH), Epizyme (EPZM), Inflarx (IFRX), Turning Point Therapeutics (TPTX), Eidos Therapeutics (EIDX), Clementia Pharmaceuticals (CMTA) and Amphastar Pharmaceuticals (AMPH). What other stocks do shareholders of Abeona Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Abeona Therapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Sangamo Therapeutics (SGMO), Micron Technology (MU), Energy Transfer LP Unit (ET), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), Opko Health (OPK), TherapeuticsMD (TXMD), AbbVie (ABBV) and Alibaba Group (BABA). Who are Abeona Therapeutics' key executives? Abeona Therapeutics' management team includes the folowing people: Mr. Steven H. Rouhandeh, Exec. Chairman (Age 61)Dr. Timothy J. Miller, Pres, Chief Scientific Officer & Director (Age 46)Mr. Jeffrey Blaine Davis, Chief Operating Officer (Age 55)Mr. Carsten Thiel, Chief Exec. Officer (Age 54)Mr. Stephen B. Thompson, Sr. VP of Fin. and Admin., Chief Accounting Officer, Sec. & Treasurer (Age 64) Who are Abeona Therapeutics' major shareholders? Abeona Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (8.58%), BlackRock Inc. (4.83%), Opaleye Management Inc. (1.14%), Northern Trust Corp (0.83%), Geode Capital Management LLC (0.79%) and Schonfeld Strategic Advisors LLC (0.45%). Company insiders that own Abeona Therapeutics stock include Stefano Buono and Stephen B Howell. View Institutional Ownership Trends for Abeona Therapeutics. Which institutional investors are selling Abeona Therapeutics stock? ABEO stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, JPMorgan Chase & Co., Northern Trust Corp, WS Management Lllp, Morgan Stanley, Marshall Wace North America L.P., Altshuler Shaham Ltd and TD Asset Management Inc.. View Insider Buying and Selling for Abeona Therapeutics. Which institutional investors are buying Abeona Therapeutics stock? ABEO stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Opaleye Management Inc., BlackRock Inc., Geode Capital Management LLC, Fosun International Ltd, Nisa Investment Advisors LLC, State of Wisconsin Investment Board and SG Americas Securities LLC. Company insiders that have bought Abeona Therapeutics stock in the last two years include Stefano Buono and Stephen B Howell. View Insider Buying and Selling for Abeona Therapeutics. How do I buy shares of Abeona Therapeutics? Shares of ABEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Abeona Therapeutics' stock price today? One share of ABEO stock can currently be purchased for approximately $7.05. How big of a company is Abeona Therapeutics? Abeona Therapeutics has a market capitalization of $346.59 million and generates $3 million in revenue each year. The biopharmaceutical company earns $-56,670,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. What is Abeona Therapeutics' official website? The official website for Abeona Therapeutics is http://www.abeonatherapeutics.com/. How can I contact Abeona Therapeutics? Abeona Therapeutics' mailing address is 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219. The biopharmaceutical company can be reached via phone at 214-665-9495 or via email at [email protected] MarketBeat Community Rating for Abeona Therapeutics (NASDAQ ABEO)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 398 (Thanks for Voting!)Underperform Votes: 250 (Thanks for Voting!)Total Votes: 648MarketBeat's community ratings are surveys of what our community members think about Abeona Therapeutics and other stocks. Vote "Outperform" if you believe ABEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABEO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/22/2019 by MarketBeat.com StaffFeatured Article: Google Finance Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.